Law360, New York (February 08, 2008, 12:00 AM ET) -- A jury has said Novartis AG unit CIBA Vision Corp. must pay $41 million for allegedly violating a Rembrandt Vision Technologies LP patent for a treatment that allows users to wear their contact lenses for extended periods.
On Wednesday, following four days of testimony, the jury in the U.S. District Court for the Eastern District of Texas held that CIBA's Focus Night and Day and O2Optix soft contact lenses infringed and induced infringement on Rembrandt’s patent.
The jury did not find that infringement was willful....
Novartis Ordered To Pay $41M In Contact Lens Spat
To view the full article, take a free trial now.
